ORF45 of Kaposi's sarcoma-associated herpesvirus inhibits phosphorylation of interferon regulatory factor 7 by IKKe and TBK1 as an alternative substrate

Journal of Virology

Volumn 86, Issue 18, 2012, Pages 10162-10172

  Liang, Qiming ^a   Fu, Bishi ^a   Wu, Fayi ^a   Li, Xiaojuan ^a   Yuan, Yan ^b   Zhu, Fanxiu ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE EPSILON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; SERINE; TRAF FAMILY MEMBER ASSOCIATED NF KAPPA B ACTIVATOR BINDING KINASE 1; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MOLECULAR DYNAMICS; MUTATION RATE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; VIRUS VIRULENCE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BINDING, COMPETITIVE; DNA, VIRAL; HEK293 CELLS; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; I-KAPPA B KINASE; IMMEDIATE-EARLY PROTEINS; INTERFERON REGULATORY FACTOR-7; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SERINE; SUBSTRATE SPECIFICITY;

HUMAN HERPESVIRUS 8;

EID: 84866166950     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05224-11     Document Type: Article

References (69)

1. Adli M, Baldwin AS. 2006. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J. Biol. Chem. 281:26976-26984.
2. Alff PJ, Sen N, Gorbunova E, Gavrilovskaya IN, Mackow ER. 2008. The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation. J. Virol. 82:9115-9122.
3. Barbie DA, et al. 2009. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112.
4. Boehm JS, et al. 2007. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079.
5. Buettner N, et al. 2010. Thogoto virus ML protein is a potent inhibitor of the interferon regulatory factor-7 transcription factor. J. Gen. Virol. 91:220-227.
6. Chang TH, et al. 2009. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5:e1000493. doi:10.1371/journal.ppat.1000493.
7. Chang Y, et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
8. Chau TL, et al. 2008. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem. Sci. 33:171-180.
9. Chen W, et al. 2008. Contribution of Ser386 and Ser396 to activation of interferon regulatory factor 3. J. Mol. Biol. 379:251-260.
10. Clement JF, Meloche S, Servant MJ. 2008. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 18:889-899.
11. Coscoy L. 2007. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat. Rev. Immunol. 7:391-401.
12. Dragan AI, Hargreaves VV, Makeyeva EN, Privalov PL. 2007. Mechanisms of activation of interferon regulator factor 3: the role of C-terminal domain phosphorylation in IRF-3 dimerization and DNA binding. Nucleic Acids Res. 35:3525-3534.
13. Fitzgerald KA, et al. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:491-496.
14. Friedman CS, et al. 2008. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 9:930-936.
15. Ganem D. 2007. Kaposi's sarcoma-associated herpesvirus, p 2847-2888. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
16. Ganem D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J. Clin. Invest. 120:939-949.
17. Greene W, et al. 2007. Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat. Res. 133:69-127.
18. Guo B, Cheng G. 2007. Modulation of the interferon antiviral response by the TBK1/IKKi adaptor protein TANK. J. Biol. Chem. 282:11817-11826.
19. Hiscott J. 2007. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282:15325-15329.
20. Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349-360.
21. Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658.
22. Honda K, et al. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777.
23. Huang J, et al. 2005. SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways. EMBO J. 24:4018-4028.
24. Hutti JE, et al. 2009. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol. Cell 34:461-472.
25. Joo CH, et al. 2007. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J. Virol. 81:8282-8292.
26. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131-137.
27. Kuang E, Fu B, Liang Q, Myoung J, Zhu F. 2011. Phosphorylation of eukaryotic translation initiation factor 4B (EIF4B) by open reading frame 45/p90 ribosomal S6 kinase (ORF45/RSK) signaling axis facilitates protein translation during Kaposi sarcoma-associated herpesvirus (KSHV) lytic replication. J. Biol. Chem. 286:41171-41182.
28. Kuang E, Tang Q, Maul GG, Zhu F. 2008. Activation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replication. J. Virol. 82:1838-1850.
29. Kuang E, Wu F, Zhu F. 2009. Mechanism of sustained activation of ribosomal S6 kinase (RSK) and ERK by Kaposi sarcoma-associated herpesvirus ORF45: multiprotein complexes retain active phosphorylated ERK and RSK and protect them from dephosphorylation. J. Biol. Chem. 284:13958-13968.
30. Lee HR, Kim MH, Lee JS, Liang C, Jung JU. 2009. Viral interferon regulatory factors. J. Interferon Cytokine Res. 29:621-627.
31. Li X, Zhu F. 2009. Identification of the nuclear export and adjacent nuclear localization signals for ORF45 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 83:2531-2539.
32. Liang C, Lee JS, Jung JU. 2008. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. Semin. Cancer Biol. 18:423-436.
33. Liang Q, Deng H, Sun CW, Townes TM, Zhu F. 2011. Negative regulation of IRF7 activation by activating transcription factor 4 suggests a cross-regulation between the IFN responses and the cellular integrated stress responses. J. Immunol. 186:1001-1010.
34. Lin R, Heylbroeck C, Pitha PM, Hiscott J. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-2996.
35. Lin R, Mamane Y, Hiscott J. 2000. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275:34320-34327.
36. Lu LL, Puri M, Horvath CM, Sen GC. 2008. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J. Biol. Chem. 283:14269-14276.
37. Marie I, Smith E, Prakash A, Levy DE. 2000. Phosphorylation-induced dimerization of interferon regulatory factor 7 unmasks DNA binding and a bipartite transactivation domain. Mol. Cell. Biol. 20:8803-8814.
38. Matsui K, et al. 2006. Cutting edge: role of TANK-binding kinase 1 and inducible IkappaB kinase in IFN responses against viruses in innate immune cells. J. Immunol. 177:5785-5789.
39. Mori M, et al. 2004. Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. J. Biol. Chem. 279:9698-9702.
40. Myoung J, Ganem D. 2011. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods 174:12-21.
41. Ning S, Pagano JS, Barber GN. 2011. IRF7: activation, regulation, modification and function. Genes Immun. 12:399-414.
42. Paz S, et al. 2006. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell Mol. Biol. (Noisy-le-grand) 52:17-28.
43. Pichlmair A, Reis e Sousa C. 2007. Innate recognition of viruses. Immunity 27:370-383.
44. Prins KC, Cardenas WB, Basler CF. 2009. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 83:3069-3077.
45. Randall RE, Goodbourn S. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89:1-47.
46. Rezaee SA, Cunningham C, Davison AJ, Blackbourn DJ. 2006. Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J. Gen. Virol. 87:1781-1804.
47. Ryzhakov G, Randow F. 2007. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J. 26:3180-3190.
48. Sathish N, Zhu FX, Golub EE, Liang Q, Yuan Y. 2011. Mechanisms of autoinhibition of IRF-7 and a probable model for inactivation of IRF-7 by Kaposi's sarcoma-associated herpesvirus protein ORF45. J. Biol. Chem. 286:746-756.
49. Sato M, et al. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13:539-548.
50. Schroder M, Baran M, Bowie AG. 2008. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J. 27:2147-2157.
51. Servant MJ, Grandvaux N, tenOever BR, Duguay D, Lin R, Hiscott J. 2003. Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. J. Biol. Chem. 278:9441-9447.
52. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151.
53. Siu KL, et al. 2009. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3 · TANK · TBK1/IKKe complex. J. Biol. Chem. 284:16202-16209.
54. Soulat D, et al. 2008. The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J. 27:2135-2146.
55. Speck SH, Ganem D. 2010. Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 8:100-115.
56. Staskus KA, et al. 1997. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71:715-719.
57. Tanaka Y, Chen ZJ. 2012. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal. 5:ra20. doi:10.1126/scisignal.2002521.
58. Unterstab G, et al. 2005. Viral targeting of the interferon-β-inducing Traf family member-associated NF-κB activator (TANK)-binding kinase-1. Proc. Natl. Acad. Sci. U. S. A. 102:13640-13645.
59. Wang H, Ryu WS. 2010. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog. 6:e1000986. doi:10.1371/journal.ppat.1000986.
60. Wu L, et al. 2009. Epstein-Barr virus LF2: an antagonist to type I interferon. J. Virol. 83:1140-1146.
61. Yu S, et al. 2010. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J. Gen. Virol. 91:2080-2090.
62. Zhang M, et al. 2008. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J. Biol. Chem. 283:18621-18626.
63. Zhou FC, et al. 2002. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J. Virol. 76:6185-6196.
64. Zhu FX, Chong JM, Wu L, Yuan Y. 2005. Virion proteins of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79:800-811.
65. Zhu FX, Cusano T, Yuan Y. 1999. Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J. Virol. 73:5556-5567.
66. Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y. 2002. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc. Natl. Acad. Sci. U. S. A. 99:5573-5578.
67. Zhu FX, Li X, Zhou F, Gao SJ, Yuan Y. 2006. Functional characterization of Kaposi's sarcoma-associated herpesvirus ORF45 by bacterial artificial chromosome-based mutagenesis. J. Virol. 80:12187-12196.
68. Zhu FX, Sathish N, Yuan Y. 2010. Antagonism of host antiviral responses by Kaposi's sarcoma-associated herpesvirus tegument protein ORF45. PLoS One 5:e10573. doi:10.1371/journal.pone.0010573.
69. Zhu FX, Yuan Y. 2003. The ORF45 protein of Kaposi's sarcoma-associated herpesvirus is associated with purified virions. J. Virol. 77:4221-4230.